Knight Therapeutics (TSX:GUD) FCF Margin % : 21.86% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Knight Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was C$16.2 Mil. Knight Therapeutics's Revenue for the three months ended in Dec. 2023 was C$74.2 Mil. Therefore, Knight Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 21.86%.

As of today, Knight Therapeutics's current FCF Yield % is 4.33%.

The historical rank and industry rank for Knight Therapeutics's FCF Margin % or its related term are showing as below:

TSX:GUD' s FCF Margin % Range Over the Past 10 Years
Min: -76.89 Med: 7.23 Max: 761.91
Current: 7.73

During the past 11 years, the highest FCF Margin % of Knight Therapeutics was 761.91%. The lowest was -76.89%. And the median was 7.23%.

TSX:GUD's FCF Margin % is ranked better than
72.49% of 1025 companies
in the Drug Manufacturers industry
Industry Median: -0.67 vs TSX:GUD: 7.73

Knight Therapeutics FCF Margin % Historical Data

The historical data trend for Knight Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics FCF Margin % Chart

Knight Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

3.47

-16.48

-73.75

6.53

7.92

Knight Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-0.02	-4.94	-1.83	18.26	21.86

Competitive Comparison of Knight Therapeutics's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Knight Therapeutics's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's FCF Margin % falls into.

Knight Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Knight Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	25.981	/	328.199
	=	7.92 %

Knight Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	16.221	/	74.197
	=	21.86 %

Knight Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Knight Therapeutics (TSX:GUD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

KHTRF:USA

Address

3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8

Website

https://www.gud-knight.com

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Ltin America and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

Executives

Sime Armoyan

10% Security Holder

Knight Therapeutics (TSX:GUD) Headlines

No Headlines